Other fluorinated pyrimidines in the treatment of solid tumors

ONCOLOGY

Volumn 15, Issue 1 SUPPL. 2, 2001, Pages 65-68

  Saad, Everardo D ^a   Hoff, Paulo M ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; EMITEFUR; FLUOROURACIL; OXONIC ACID; PYRIDINE DERIVATIVE; S 1 (COMBINATION); TEGAFUR;

CLINICAL TRIAL; DRUG COMBINATION; HUMAN; NEOPLASM; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; NEOPLASMS; OXONIC ACID; PYRIDINES; TEGAFUR;

EID: 0035222170     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Heidelberger C, Chaudhuri NK, Dannenberg, et al: Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179:663-666, 1957.
2. Schilsky RL: Biochemical and clinical pharmacology of 5-fluorouracil. Oncology (Huntingt) 12(10 suppl 7):13-18, 1998.
3. Hiller SA, Zhuk RA, Lidak MY: Analogs of pyridine nucleosides. Dokl Akad Nauk 176:332-335, 1967.
4. Valdivieso M, Bodey GP, Gottlieb JA, et al: Clinical evaluation of ftorafur (pyrimidine-deoxyribose nl-2′-furanidyl-5-fluorouracil). Cancer Res 36:1821-1824, 1976.
5. Friedman MA, Ignoffo RJ: A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958). Cancer Treat Rev 7:205-213, 1980.